Avid Radiopharmaceuticals Announces Positive Interim Results from Phase III Clinical Trial of Amyloid Imaging Agent Florbetapir F18
Our partner company, Avid Radiopharmaceuticals, announced positive interim results from the Phase III clinical trial of its amyloid imaging agent Florbetapir F18 for early diagnosis…
Posted by